A Phase I Safety and Window-of-Opportunity Study of Preoperative Intra-tumoral Injection of OX40-Ligand Expressing Oncolytic Adenovirus (DNX-2440) in Patients with Resectable Liver Metastasis
A Phase I safety and window-of-opportunity study of preoperative intra-tumoral injection of OX40-ligand expressing oncolytic adenovirus (DNX-2440) in patients with resectable liver metastasis
the primary objective is to establish safety of DNX-2440 preoperative sequential intratumoral injection and to determine the maximum tolerated dose in patients with liver metastasis (secondary liver cancer). Secondary objectives will include: To determine efficacy of DNX-2440 in achieving tumor cell killing of injected and bystander tumors To determine viral replication ability in injected tumor To measure immunotherapeutic responses following intratumoral injection of DNX-2440 in liver metastasis prior to surgical resection of the tumors (liver resection)
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.